Scarica l'app Stockscreener
27.21
1.87%
0.50
Dopo l'orario di chiusura:
27.21
Precedente Chiudi:
$26.71
Aprire:
$27.22
Volume 24 ore:
830.69K
Relative Volume:
0.58
Capitalizzazione di mercato:
$2.40B
Reddito:
-
Utile/perdita netta:
$-151.78M
Rapporto P/E:
-13.21
EPS:
-2.0595
Flusso di cassa netto:
$-136.42M
1 W Prestazione:
+1.87%
1M Prestazione:
+1.99%
6M Prestazione:
-17.14%
1 anno Prestazione:
+90.01%
Intervallo 1D:
$27.11
$28.19
Intervallo di 1 settimana:
$25.92
$28.19
Portata 52W:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
27.21 | 2.35B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | TD Cowen | Buy |
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
New Mineralys hires receive stock awards vesting over four years - Stock Titan
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics, Inc. Revenue Breakdown – NASDAQ:MLYS - TradingView
MLYS|Mineralys Therapeutics Inc|Price:27.920|Chg%:+1.210 - TradingKey
MLYS|Mineralys Therapeutics Inc|Price:26.730|Chg%:-0.270 - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common shares - Bitget
Form 4 Mineralys Therapeutics Inc For: 23 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $199k in shares - Investing.com
Mineralys (NASDAQ: MLYS) CCO sells 7,438 shares after option exercise - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 21 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise - Stock Titan
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares - Investing.com
Mineralys Therapeutics, Inc. (MLYS): Analyst Consensus Points to a Promising 83% Upside Potential - DirectorsTalk Interviews
Mineralys CMO David Malcom Rodman disposes of 416 common shares worth $11,036.48 - Bitget
Responsive Playbooks and the MLYS Inflection - Stock Traders Daily
Form 144 Mineralys Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise - Stock Titan
Mineralys Executive Stock Sale Analysis - Intellectia AI
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date - The Motley Fool
What to Know About This Mineralys Insider Sale Before a December FDA Date - The Motley Fool
Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Mineralys Therapeutics (MLYS) Q3 2025 earnings summary - Quartr
Mineralys therapeutics CMO Rodman sells $556,671 in shares By Investing.com - Investing.com South Africa
Mineralys therapeutics CMO Rodman sells $556,671 in shares - Investing.com UK
Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock By Investing.com - Investing.com South Africa
Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options - Stock Titan
Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan - Stock Titan
Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Frontier tech research, news & data - MLQ.ai
Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Form 144 Mineralys Therapeutics For: 13 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale - Stock Titan
Mineralys Therapeutics (MLYS) insider details stock option exercise and sales - Stock Titan
Number of shareholders of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Mineralys Therapeutics CMO Rodman sells $65,781 in stock By Investing.com - Investing.com India
Mineralys Therapeutics CMO Rodman sells $65,781 in stock - Investing.com India
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):